Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pulocimab - AD Pharmaceuticals

Next Previous
Drug Profile

Pulocimab - AD Pharmaceuticals

Alternative Names: AK-109

Latest Information Update: 14 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer AD Pharmaceuticals; Akeso Biopharma
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I/II Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 02 Apr 2024 Akeso plans a phase III trial for Adenocarcinoma (Combination therapy, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Late-stage disease) (IV) in May 2024 (NCT06341335)
  • 23 Jan 2024 Pulocimab is still in phase I trial for Solid-tumours (Late-stage disease, Monotherapy, Recurrent, Refractory metastatic disease, Second-line therapy or greater, Treatment-resistant) in China (IV) (NCT04547205) (Akeso Biopharma pipeline, January 2024)
  • 23 Jan 2024 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) (IV) (Akeso Biopharma pipeline, January 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top